Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis
Open Access
- 1 June 2017
- journal article
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 5, 41-61
Abstract
No abstract availableKeywords
Funding Information
- Genelux Corporation
- University of Wuerzburg
- Genelux Corporation
This publication has 67 references indexed in Scilit:
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumorsJournal of Clinical Investigation, 2013
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerNature Medicine, 2013
- Preferential Colonization of Metastases by Oncolytic Vaccinia Virus Strain GLV-1h68 in a Human PC-3 Prostate Cancer Model in Nude MicePLOS ONE, 2012
- Development of Mature and Functional Human Myeloid Subsets in Hematopoietic Stem Cell-Engrafted NOD/SCID/IL2rγKO MiceThe Journal of Immunology, 2012
- Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4Gene Therapy, 2011
- Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapiesJournal of Translational Medicine, 2011
- Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competenceBlood, 2010
- Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapyProceedings of the National Academy of Sciences, 2009
- CD56bright natural killer (NK) cells: an important NK cell subsetImmunology, 2009
- The Hallmarks of CancerCell, 2000